

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **MARAPHARM VENTURES INC. (Marapharm or the “Company”)** (the “Issuer”).

Trading Symbol: **MDM**

Number of Outstanding Listed Securities: **84,842,936**

Date: **July 7, 2017**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.
 - *With regards to Nevada, all three medical licenses have been granted State approval to cultivate and process marijuana. Further to this, all three recreational marijuana licenses have been issued. City Business Licenses have been granted. The two temporary buildings on-site passed all State inspections and construction on the two 5,000 sq. buildings has commenced.*
 - *The Company is doing due diligence on regulations and licensing on two properties in California.*
 - *The Company is reviewing the use of ACM (Automated Cannabis Machines) with regard to regulations in each State. It has hired GIDE to assist with the process.*
 - *With regard to Washington, the Company has decided to move ahead with the 13 acre purchase and is working with the license holder on plans that will enhance the facility to bring it to maximum production. The next phase of renovations has been approved by the County and the State.*
 - *With regards to our Canadian application under the Marijuana for Medical Purposes Regulations (MMPR), we have been updated by Health Canada with regard to the new Access to Cannabis for Medical Purposes Regulations (ACMPR) which will replace the MMPR, and will be revising our application to include the new regulations, as well as amending the application to allow for processing, while at the same time maintaining our position in the application process.*

2. Provide a general overview and discussion of the activities of management.
 - *With regard to operations in Nevada, a timeline has been formulated and construction has commenced of the cultivation and processing facilities.*
 - *With regard to Washington, the Company is working on designs to enhance the value of the assets acquired, with the purchase of new equipment and building improvements. The next phase of renovations has been approved by the County and the State.*
 - *Amendments will be made to our Health Canada application to comply with the new regulations (ACMPR), as well as adjusting its current application to include the processing of medical marijuana.*

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
 - *The Company has entered into an agreement for a transportation delivery service located in Palm Desert California and investigation into the Nevada and Arizona markets is currently underway with the assistance of GIDE Consulting.*

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

No products or services have been discontinued.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

No new business relationships have been entered into.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

No contracts are set to expire or terminate. No financing previously announced has been cancelled.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable

together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

On June 7th, 2017, the Company closed on a transaction in California to acquire 1.22 acres of land, 2 provisional licenses and complete permitting for an approved marijuana cultivation and processing facility. Purchase price was \$1,125,000 US.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

With regard to Nevada, all three licenses have been granted State approval to cultivate and process both medical and recreational marijuana.

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

There is no new hiring.

11. Report on any labour disputes and resolutions of those disputes if applicable.

There are no labour disputes.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Marapharm was served with a notice of claim in small claims court by Armadillo Resources Inc. for the amount \$16,176.00, for unpaid rent. The Company intends to dispute the claim, as no contract was ever entered into with Armadillo Resources Inc. for the payment of rent. A Settlement Conference in the Provincial Small Claims Court was held on March 15, 2017 and the matter was adjourned generally.

Marapharm was served with the same notice of claim by Armadillo Resources Inc. for unpaid rent. The Company intends to dispute the claim, as no contract was ever entered into with Armadillo Resources Inc. for the payment of rent. A Settlement Conference in the Provincial Small Claims Court is set for August 30, 2017.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

The Company entered into three debt settlement agreements with regard to its operations in Nevada:

- 1) *Jason Weiner of Weiner Law Nevada.*
Purpose: Legal fees for license transfer and approval
Issuance: 300,000 common shares at a deemed price of .56c USD per share for payment of \$165,000.00 US.
- 2) *Ramsey Dadis*
Purpose: Consulting fees for Nevada license application.
Issuance: 60,000 common shares at a deemed price of .75c US per share for payment of \$45,000.00 US.
- 3) *Jason Schuck*
Purpose: Consulting fees for Nevada license application.
Issuance: 15,000 common shares at a deemed price of .75c USD per share for payment of \$11,250.00 US.

14. Provide details of any securities issued and options or warrants granted.

| Security | Number Issued | Details of Issuance | Use of Proceeds ⁽¹⁾ |
|---------------|---------------|---------------------|---|
| Common Shares | 300,000 | Debt Settlement | To pay legal fees in Nevada for license transfer and application. |
| Common Shares | 60,000 | Debt Settlement | To pay consulting fees for license application in Nevada. |
| Common Shares | 15,000 | Debt settlement | To pay consulting fees for license application in Nevada. |

| | | | |
|---------------|-----------|-------------------------------------|---|
| Common Shares | 650,000 | Stock Options | The proceeds will be used for the development of the Washington and Nevada projects and for general corporate purposes. |
| Common Shares | 1,880,500 | Warrants – Expired on June 17, 2017 | The proceeds will be used for the development of the Washington and Nevada projects and for general corporate purposes. |
| Common Shares | 1,062,500 | Warrants – Expire on Sept 6, 2017 | The proceeds will be used for the development of the Washington and Nevada projects and for general corporate purposes. |

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

There is nothing to report this filing.

16. Provide details of any changes in directors, officers or committee members.
There have been no changes in directors, officers or committee members.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

With regard to Nevada, the legalization and implementation of the recreational marijuana program.

With regard to Washington, Washington State has dismantled the medical marijuana initiative (I-692) in favour of the more regulated I-502. This removes the medical marijuana cultivators but allows medical dispensaries to dispense medical and recreational marijuana. As a result of these regulatory changes, marijuana sales in Washington have broken all prior records over the last 4 months.

The Prime Minister of Canada has announced the legalization of recreational marijuana for 2018.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated July 7, 2017.

Linda Sampson
Name of Director or Senior
Officer

"Linda Sampson"
Signature
CEO

Official Capacity

| | | |
|--|-------------------------------|---|
| Issuer Details Name of Issuer Marapharm Ventures Inc. | For Month End June 2017 | Date of Report YY/MM/D 2017/07/07 |
| Issuer Address 102-1561 Sutherland Avenue | | |
| City/Province/Postal Code Kelowna, BC V1Y 5Y7 | Issuer Fax No. () | Issuer Telephone No. (778)583-4476 |

FORM 7 – MONTHLY PROGRESS REPORT

July 7, 2017
Page 6

| | | |
|---|---------------------------------------|---|
| Contact Name Linda Sampson | Contact Position CEO | Contact Telephone No. (778) 583-4476 |
| Contact Email Address Office@marapharm.com | Web Site Address www.marapharm.com | |

FORM 7 – MONTHLY PROGRESS REPORT

July 7, 2017
Page 7